Review Article
/ VOLUME 4, ISSUE 4, DECEMBER 2022
HIV Pre-Exposure Prophylaxis in Central and Eastern Europe-Gains and Challenges in An Ever-Changing World
It has been more than a decade since the first evidence of oral pre-exposure prophylaxis (PrEP) in the “Iniciativa Profilaxis Pre-Exposición” (iPreEx) study, which reported 44% efficacy. Following these results, the US Food and Drug Administration (FDA) approved PrEP in 2012 as a method of prevention from HIV for individuals at high risk, and two years later, the Centers for Disease Control and Prevention (CDC) published the PrEP guidelines. Then, many other (...) Read More